Introduction: Increasing antibiotic resistance also has an impact on perioperative antibiotic prophylaxis (PAP). This narrative review evaluates fosfomycin trometamol (FT) as PAP in endourological interventions. Materials and Methods: Nine clinical studies including 4 randomized comparative studies were analyzed. A total of 1,614 patients received FT as PAP for different endourological procedures and extracorporeal shock wave lithotripsy [ESWL; i.e. cystoscopy (n = 498), urodynamic studies (n = 39), ureteropyeloscopy (n = 10), urethrotomy (n = 20), lithotripsy (n = 15), transurethral resection of bladder tumors (n = 139), transurethral resection of the prostate (n = 843), ESWL (n = 20), ureterorenoendoscopic lithotripsy (n = 18), percutaneous nephrostomic lithotripsy (n = 12)]. Results: In 8 clinical studies, FT was shown to be effective in preventing healthcare-associated urinary tract infections (HAUTIs). One study showed no benefit. The usual dosage regimen was oral administration of 3 g of FT 3 h before and 24 h after the procedure. In 1 randomized comparative study investigating HAUTIs after diagnostic cystoscopy, it could also be shown that a single oral dose of 3 g of FT 3 h before cystoscopy was as effective as a double dose. Conclusion: According to the published results, for traumatic endourological interventions and surgical procedures, an oral dosage of 3 g of FT 3 h before and 24 h after the procedure and only 1 (prior) oral dosage for diagnostic procedures might be an alternative if PAP is indicated. Limitations of the studies are the low numbers of patients included for most indications.

Keywords:
Fosfomycin trometamol, Perioperative antibiotic prophylaxis, Healthcare-associated infections, Endourological interventions
1.
Pittet D: Healthcare-associated infection: moving behind headlines to clinical solutions. J Hosp Infect 2009;73:293-295.
2.
Gastmeier P, Kampf G, Wischnewski N, Hauer T, Schulgen G, Schumacher M, et al: Prevalence of nosocomial infections in representative German hospitals. J Hosp Infect 1998;38:37-49.
3.
Grabe M, Bjerklund-Johansen TE, Botto H, Wullt B, Çek M, Naber KG, Pickard RS, Tenke P, Wagenlehner F: Guidelines on Urological Infections. EAU Guidelines, edition presented at the 278th EAU Annual Congress, Milan 2013.
4.
Cek M, Tandogdu Z, Naber K, Tenke P, Wagenlehner F, van Oostrum E, et al: Antibiotic prophylaxis in urology departments, 2005-2010. Eur Urol 2012;63:386-394.
5.
Fosfomycin Trometamol. Product Monograph. Milan, Springer Healthcare Italia, 2012.
6.
Kahlmeter G, Poulsen HO: Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012;39:45-51.
7.
Hosbul T, Ozyurt M, Baylan O, Bektore B, Ardic N, Ceylan S, et al: In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections (in Turkish). Mikrobiyol Bul 2009;43:645-649.
8.
Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S: Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007;29:62-65.
9.
Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al: Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897-1902.
10.
Periti P, Novelli A, Reali EF, Del Bono GP, Fontana P: Prophylactic chemotherapy with fosfomycin trometamol salt in transurethral prostatectomy. A controlled clinical trial; in Neu HC, Williams JD (eds): New Trends in Urinary Tract Infections. The Single-Dose Therapy International Symposium, Rome, January 1987. Basel, Karger, 1988, pp 207-233.
11.
Periti P, Novelli A, Reali EF, Lamanna S, Fontana P: Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial. Eur Urol 1987;13(suppl 1):122-131.
12.
Di Silverio F, Cruciani E, Ferrone G, Prencipe MG, Lauretti S, Fini D: Evaluation of fosfomycin trometamol in the prevention of urinary tract infections after ESWL and ureteropyeloscopy; in Neu HC, Williams JD (eds): New Trends in Urinary Tract Infections. The Single-Dose Therapy International Symposium, Rome, January 1987. Basel, Karger, 1988, pp 329-332.
13.
Baert L, Billiet I, Vandepitte J: Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection 1990;18(suppl 2):S103-S106.
14.
Di Silverio F, Ferrone G, Carati L: Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study. Infection 1990;18(suppl 2):S98-S102.
15.
Selvaggi FP, Battaglia M, Grossi FS, Disabato G, Cormio L: Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience. Infection 1992;20(suppl 4):S321-S324.
16.
Nicoletti G, Nicolosi D, Schito GC, Varaldo M, Carati L: Fosfomycin trometamol in prophylaxis of bacteriuria associated with transurethral diagnostic procedures. Urogynaecologia 1994;8:123-134.
17.
Szopinski T, Antoniewicz AA, Borówka A: The prophylactic use of phosphomycin in endoscopic procedures associated urinary tract infections (in Polish). Urol Pol 2002;55:1- 7.
18.
Jimenez-Pacheco A, Lardelli Claret P, Lopez Luque A, Lahoz-Garcia C, Arrabal Polo MA, Nogueras Ocana M: Randomized clinical trial on antimicrobial prophylaxis for flexible urethrocystoscopy. Arch Esp Urol 2012;65:542-549.
19.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52: e103-e120.
20.
Wagenlehner FME, Schmiemann G, Hoyme U, Fünfstück R, Hummers-Pradier E, Kaase M, Kniehl E, Selbach I, Sester U, Vahlensiek W, Watermann D, Naber KG: Epidemiology, diagnostics, therapy and management of uncomplicated bacterial community acquired urinary tract infections in adults. Short version 17 June 2010. Chemother J 2011;20:158-168.
21.
Naber KG, Schito G, Botto H, Palou J, Mazzei T: Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54:1164-1175.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.